Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 10/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590886 | 1.00 | CDC25A (0.40) | CDC25ACES1MEN1KMT2AALDH1A1 | |
| SCHEMBL591245 | 1.00 | CDC25A (0.40) | CDC25ACES1MEN1KMT2AALDH1A1 | |
| SCHEMBL7708382 | 0.99 | ALDH1A1 (0.39) | CDC25ACES1MEN1KMT2AALDH1A1 | |
| SCHEMBL19656192 | 0.95 | CYP1A2 (0.35) | CDC25ACES1MEN1KMT2AALDH1A1 | |
| SCHEMBL1110825 | 0.95 | DRD2 (0.34) | CDC25ACES1MEN1KMT2AALDH1A1 | |
| SCHEMBL285430 | 0.89 | CHRM2 (0.31) | MEN1KMT2A | |
| SCHEMBL284859 | 0.86 | TDP1 (0.43) | MEN1KMT2AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL285328 | 0.86 | HTR1A (0.33) | CES1MEN1KMT2A | |
| SCHEMBL284852 | 0.84 | SMN1; SMN2 (0.39) | ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL284958 | 0.81 | NAMPT (0.39) | MEN1KMT2AALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116908158-A | Drug mitochondrial toxicity detection method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-10-20 | — | — | CN | claimed |
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | LUNELLA BIOTECH, INC. (CA) | 2023-06-13 | — | — | US | claimed |
| US-20220249438-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2022-08-11 | — | — | US | claimed |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH, INC. (CA) | 2022-06-30 | — | — | US | claimed |
| EP-3989963-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2022-05-04 | — | — | EP | claimed |
| CN-114173773-A | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | 卢内拉生物技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-20220040316-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2022-02-10 | — | — | US | claimed |
| US-20220016151-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | LUNELLA BIOTECH, INC. (CA) | 2022-01-20 | — | — | US | claimed |
| CN-113573715-A | Triple therapy for targeting mitochondria and killing cancer stem cells | 卢内拉生物技术有限公司 | 2021-10-29 | — | — | CN | claimed |
| EP-3897658-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | claimed |
| EP-3897659-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | claimed |
| CN-113453690-A | Triple therapy for anti-aging | 卢内拉生物技术有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113164504-A | Azithromycin and roxithromycin derivatives as antiageing agents | 卢内拉生物技术有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210215702-A1 | BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE | LUNELLA BIOTECH, INC. (CA) | 2021-07-15 | — | — | US | claimed |
| US-20210137925-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | LUNELLA BIOTECH, INC. (CA) | 2021-05-13 | — | — | US | claimed |
| WO-2020264246-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-12-30 | — | — | WO | claimed |
| WO-2020242857-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH, INC. (CA) | 2020-12-03 | — | — | WO | claimed |
| WO-2020131704-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | claimed |
| WO-2020131696-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | claimed |
| EP-3882603-B1 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND COMPUTER PROGRAM | SONY GROUP CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250362230-A1 | FLUORESCENCE INTENSITY CORRECTING METHOD, FLUORESCENCE INTENSITY CALCULATING METHOD, AND FLUORESCENCE INTENSITY CALCULATING APPARATUS | SONY CORP (JP) | 2025-11-27 | — | — | US | disclosed |
| US-12399122-B2 | Fluorescence intensity correcting method, fluorescence intensity calculating method, and fluorescence intensity calculating apparatus | SONY CORPORATION (JP) | 2025-08-26 | — | — | US | disclosed |
| EP-4486315-A1 | COMPOSITIONS FOR PREVENTING AND TREATING INFECTION COMPRISING AN ARTIFICIAL SWEETENER | Brunel University London (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-113164504-B | Azithromycin and roxithromycin derivatives as anti-aging agents | 卢内拉生物技术有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240377311-A1 | METHODS FOR IMAGE-BASED DETECTION AND SORTING AND SYSTEMS FOR SAME | BECTON DICKINSON CO (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240377325-A1 | METHODS FOR ASSESSING CELL MITOCHONDRIAL MORPHOLOGY AND SYSTEMS FOR SAME | BECTON, DICKINSON AND COMPANY | 2024-11-14 | — | — | US | disclosed |
| EP-4462102-A1 | METHODS FOR IMAGE-BASED DETECTION AND SORTING AND SYSTEMS FOR SAME | Becton, Dickinson and Company (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4462387-A1 | METHODS FOR ASSESSING CELL MITOCHONDRIAL MORPHOLOGY AND SYSTEMS FOR SAME | Becton, Dickinson and Company (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-114173773-B | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | 卢内拉生物技术有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240180944-A1 | AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGS | LUNELLA BIOTECH, INC. (CA) | 2024-06-06 | — | — | US | disclosed |
| EP-3813949-B1 | ENERGETIC\" CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | LUNELLA BIOTECH INC (CA) | 2024-05-29 | — | — | EP | disclosed |
| US-11994468-B2 | Fluorescence intensity correcting method, fluorescence intensity calculating method, and fluorescence intensity calculating apparatus | SONY CORPORATION (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20240159673-A1 | FLUORESCENCE INTENSITY CORRECTING METHOD, FLUORESCENCE INTENSITY CALCULATING METHOD, AND FLUORESCENCE INTENSITY CALCULATING APPARATUS | SONY CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| CN-114787287-B | Fluorescent acridine salt, synthesis thereof and application thereof in detection of cardiolipin | 拉脱维亚有机合成学院 | 2024-05-07 | — | — | CN | disclosed |
| US-11957700-B2 | Azithromycin and roxithromycin derivatives as senolytic drugs | LUNELLA BIOTECH, INC. (CA) | 2024-04-16 | — | — | US | disclosed |
| US-11918597-B2 | Triple combination therapies for anti-aging | LUNELLA BIOTECH, INC. (CA) | 2024-03-05 | — | — | US | disclosed |
| EP-4200609-B1 | AN ASSAY FOR MEASURING BINDING AFFINITY FOR CARDIOLIPIN OF BIOLOGICALLY ACTIVE COMPOUNDS | LATVIAN INST ORGANIC SYNTHESIS (LV) | 2023-12-27 | — | — | EP | disclosed |
| EP-4065643-B1 | FLUORESCENT ACRIDINIUM SALTS, SYNTHESIS THEREOF AND USE FOR DETECTION OF CARDIOLIPIN | LATVIAN INST ORGANIC SYNTHESIS (LV) | 2023-12-13 | — | — | EP | disclosed |
| US-11842798-B2 | Natural product and genetic data analysis and discovery system, method and computational platform therefor | ADAPSYN BIOSCIENCE INC. (CA) | 2023-12-12 | — | — | US | disclosed |
| CN-116908158-A | Drug mitochondrial toxicity detection method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023199057-A1 | COMPOSITIONS FOR PREVENTING AND TREATING INFECTION COMPRISING AN ARTIFICIAL SWEETENER | BRUNEL UNIVERSITY LONDON (GB) | 2023-10-19 | — | — | WO | disclosed |
| EP-3391260-B1 | A NATURAL PRODUCT AND GENETIC DATA ANALYSIS AND DISCOVERY SYSTEM, METHOD AND COMPUTATIONAL PLATFORM THEREFOR | ADAPSYN BIOSCIENCE INC (CA) | 2023-08-23 | — | — | EP | disclosed |
| US-20230243840-A1 | An assay for measuring binding affinity for cardiolipin of biologically active compounds | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2023-08-03 | — | — | US | disclosed |
| EP-4200609-A1 | AN ASSAY FOR MEASURING BINDING AFFINITY FOR CARDIOLIPIN OF BIOLOGICALLY ACTIVE COMPOUNDS | Latvian Institute Of Organic Synthesis (LV) | 2023-06-28 | — | — | EP | disclosed |
| CN-116097101-A | Assay for measuring the binding affinity of biologically active compounds to cardiolipin | 拉脱维亚有机合成学院 | 2023-05-09 | — | — | CN | disclosed |
| US-20230140688-A1 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | SP NUTRACEUTICALS INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230040965-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | LUNELLA BIOTECH, INC. (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11559527-B2 | Targeting mitochondrial fission through mDIVI-1 derivatives | LUNELLA BIOTECH, INC. (CA) | 2023-01-24 | — | — | US | disclosed |
| US-20230013542-A1 | Fluorescent acridinium salts, synthesis thereof and use for detection of cardiolipin | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2023-01-19 | — | — | US | disclosed |
| US-20220260491-A1 | FLUORESCENCE INTENSITY CORRECTING METHOD, FLUORESCENCE INTENSITY CALCULATING METHOD, AND FLUORESCENCE INTENSITY CALCULATING APPARATUS | SONY CORPORATION (JP) | 2022-08-18 | — | — | US | disclosed |
| US-20220249438-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2022-08-11 | — | — | US | disclosed |
| CN-114787287-A | Fluorescent acridinium salts, their synthesis and use for detection of cardiolipin | 拉脱维亚有机合成学院 | 2022-07-22 | — | — | CN | disclosed |
| US-11340167-B2 | Fluorescence intensity correcting method, fluorescence intensity calculating method, and fluorescence intensity calculating apparatus | SONY CORPORATION (JP) | 2022-05-24 | — | — | US | disclosed |
| CN-114270168-A | Information processing apparatus, information processing method, program, and information processing system | 索尼集团公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114173773-A | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | 卢内拉生物技术有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11262305-B2 | Fluorescence intensity correcting method, fluorescence intensity calculating method, and fluorescence intensity calculating apparatus | SONY CORPORATION (JP) | 2022-03-01 | — | — | US | disclosed |
| WO-2022038424-A1 | AN ASSAY FOR MEASURING BINDING AFFINITY FOR CARDIOLIPIN OF BIOLOGICALLY ACTIVE COMPOUNDS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2022-02-24 | — | — | WO | disclosed |
| US-RE48928-E1 | Lysophosphatidic acid detection | PORTLAND STATE UNIVERSITY (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040316-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2022-02-10 | — | — | US | disclosed |
| US-20220033424-A1 | FLUOROUS METAL CHELATES COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
| US-20220016151-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | LUNELLA BIOTECH, INC. (CA) | 2022-01-20 | — | — | US | disclosed |
| US-11192849-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| CN-113573715-A | Triple therapy for targeting mitochondria and killing cancer stem cells | 卢内拉生物技术有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3897658-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897659-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-11150358-B2 | Radiation dosimetry sol or gel and radiation dosimeter comprising same as material for radiation dosimetry | RIKEN (JP) | 2021-10-19 | — | — | US | disclosed |
| CN-113453690-A | Triple therapy for anti-aging | 卢内拉生物技术有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210275543-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL GENETIC DISEASES | UNIVERSITÉ PARIS CITÉ (FR) | 2021-09-09 | — | — | US | disclosed |
| US-20210275560-A1 | AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGS | LUNELLA BIOTECH, INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| US-20210254177-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | LUNELLA BIOTECH, INC. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-113164504-A | Azithromycin and roxithromycin derivatives as antiageing agents | 卢内拉生物技术有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210215702-A1 | BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE | LUNELLA BIOTECH, INC. (CA) | 2021-07-15 | — | — | US | disclosed |
| US-20210137925-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | LUNELLA BIOTECH, INC. (CA) | 2021-05-13 | — | — | US | disclosed |
| EP-3134389-B1 | QUINAZOLINE SCAFFOLD BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021046646-A1 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | SP NUTRACEUTICALS INC. (CA) | 2021-03-18 | — | — | WO | disclosed |
| EP-3791870-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-106458933-B | Quinazoline scaffold-based compounds, pharmaceutical compositions thereof, and methods of use | 泰克年研究发展基金会公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2020262970-A1 | COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY MITOCHONDRIAL DYSFUNCTION | 동아대학교 산학협력단 | 2020-12-30 | — | — | WO | disclosed |
| WO-2020262971-A1 | COMPOSITION FOR PREVENTING OR TREATING DISEASES CAUSED BY MITOCHONDRIAL DYSFUNCTION | 동아대학교 산학협력단 | 2020-12-30 | — | — | WO | disclosed |
| EP-3728300-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | Lunella Biotech, Inc. (CA) | 2020-10-28 | — | — | EP | disclosed |
| US-20200333474-A1 | RADIATION DOSIMETRY SOL OR GEL AND RADIATION DOSIMETER COMPRISING SAME AS MATERIAL FOR RADIATION DOSIMETRY | RIKEN (JP) | 2020-10-22 | — | — | US | disclosed |
| EP-3384908-B1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | UNIV COLUMBIA (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3686632-A1 | RADIATION DOSIMETRY SOL OR GEL AND RADIATION DOSIMETER COMPRISING SAME AS MATERIAL FOR RADIATION DOSIMETRY | Riken (JP) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020131696-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131704-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020118307-A1 | FLUOROUS METAL CHELATES COMPOSITIONS | THE REGENTS OF THE UNIVEFISITY OF CALIFORNIA (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3600308-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL GENETIC DISEASES | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-05 | — | — | EP | disclosed |
| US-20190292135-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-09-26 | — | — | US | disclosed |
| US-10259775-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180373833-A1 | A NATURAL PRODUCT AND GENETIC DATA ANALYSIS AND DISCOVERY SYSTEM, METHOD AND COMPUTATIONAL PLATFORM THEREFOR | MCMASTER UNIVERSITY (CA) | 2018-12-27 | — | — | US | disclosed |
| US-10113968-B2 | Specific detection and quantification of cardiolipin and isolated mitochondria by positively charged AIE fluorogens and method of manufacturing thereof | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2018-10-30 | — | — | US | disclosed |
| EP-3384908-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018178237-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL GENETIC DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-10-04 | — | — | WO | disclosed |
| US-10035780-B2 | Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2018-07-31 | — | — | US | disclosed |
| US-9952231-B2 | Lysophosphatidic acid detection | PORTLAND STATE UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-9846156-B2 | Method of treatment employing cardiac glycoside | PHOENIX BIOTECHNOLOGY, INC. | 2017-12-19 | — | — | US | disclosed |
| US-20170304251-A1 | AVOCADO-DERIVED LIPIDS FOR USE IN TREATING LEUKEMIA | SPAGNUOLO, PAUL ANTHONY (CA) | 2017-10-26 | — | — | US | disclosed |
| EP-2970325-B1 | LYSOPHOSPHATIDIC ACID DETECTION | UNIV PORTLAND STATE (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3204001-A1 | AVOCADO-DERIVED LIPIDS FOR USE IN TREATING LEUKEMIA | Spagnuolo, Paul Anthony (CA) | 2017-08-16 | — | — | EP | disclosed |
| US-20170217907-A1 | QUINAZOLINE SCAFFOLD BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2017-08-03 | — | — | US | disclosed |
| US-20170067897-A1 | Method of Treatment Employing Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3134389-A1 | QUINAZOLINE SCAFFOLD BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Technion Research & Development Foundation Limited (IL) | 2017-03-01 | — | — | EP | disclosed |
| CN-106458933-A | Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof | 泰克年研究发展基金会公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170023681-A1 | PERSONAL AND SELF INDICATING RADIATION ALERT DOSIMETER | NEW YORK UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-9494589-B2 | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160299078-A1 | Specific Detection and Quantification of Cardiolipin and Isolated Mitochondria by Positively Charged AIE Fluorogens and Method of Manufacturing Thereof | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-10-13 | — | — | US | disclosed |
| US-20160297748-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-10-13 | — | — | US | disclosed |
| EP-3076962-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016054746-A1 | AVOCADO-DERIVED LIPIDS FOR USE IN TREATING LEUKEMIA | SPAGNUOLO PAUL ANTHONY (CA) | 2016-04-14 | — | — | WO | disclosed |
| US-20160047830-A1 | LYSOPHOSPHATIDIC ACID DETECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| EP-2970325-A2 | LYSOPHOSPHATIDIC ACID DETECTION | Portland State University (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150316550-A1 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015162615-A1 | QUINAZOLINE SCAFFOLD BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-10-29 | — | — | WO | disclosed |
| CN-102313724-B | Fluorescence Intensity Compensation Method and Fluorescence Intensity Calculation Device | SONY CORP | 2015-07-22 | — | — | CN | disclosed |
| US-9086489-B2 | Personal and area self-indicating instant radiation alert dosimeter | JP LABORATORIES, INC (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015084749-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015081860-A1 | SPECIFIC DETECTION AND QUANTIFICATION OF CARDIOLIPIN AND ISOLATED MITOCHONDRIA BY POSITIVELY CHARGED AIE FLUOROGENS AND METHOD OF MANUFACTURING THEREOF | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-06-11 | — | — | WO | disclosed |
| US-8872134-B2 | Self indicating radiation alert dosimeter | JP LABORATORIES, INC (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014144561-A2 | LYSOPHOSPHATIDIC ACID DETECTION | THE OREGON STATE BOARD OF HIGHER EDUCATION ACTING BY AND THROUGH PORTLAND STATE UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130324485-A1 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| CN-101909637-B | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside | PHOENIX BIOTECHNOLOGY INC | 2013-09-18 | — | — | CN | disclosed |
| EP-2598649-A1 | METHOD, REAGENT, AND APPARATUS FOR DETECTING A CHEMICAL CHELATOR | Advanced Biomedical Limited (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-20130130272-A1 | METHOD, REAGENT, AND APPARATUS FOR DETECTING A CHEMICAL CHELATOR | ADVANCED BIOMEDICAL LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2231165-B1 | METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE | PHOENIX BIOTECHNOLOGY INC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8367363-B2 | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130022666-A1 | METHODS AND COMPOSITIONS FOR TRANSFER OF MITOCHONDRIA INTO MAMMALIAN CELLS | BRZEZINSKA ANNA (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120315627-A1 | METHOD FOR DETERMINING THE EFFECTIVENESS OF STERILIZATION AND/OR DISINFECTION PROCESS | ADVANCED BIOMEDICAL LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-8282930-B2 | Molecular delivery vehicle | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-10-09 | — | — | US | disclosed |
| US-20120205591-A1 | SELF INDICATING RADIATION ALERT DOSIMETER | PATEL GORDHABHAI N (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120181453-A1 | PERSONAL AND AREA SELF-INDICATING INSTANT RADIATION ALERT DOSIMETER | JP LABORATORIES INC. | 2012-07-19 | — | — | US | disclosed |
| US-8115182-B1 | Personal and area self-indicating radiation alert dosimeter | JP LABORATORIES INC. | 2012-02-14 | — | — | US | disclosed |
| WO-2012017194-A1 | METHOD, REAGENT, AND APPARATUS FOR DETECTING A CHEMICAL CHELATOR | ADVANCED BIOMEDICAL LIMITED (GB) | 2012-02-09 | — | — | WO | disclosed |
| US-20120012123-A1 | COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-01-19 | — | — | US | disclosed |
| CN-102313724-A | Fluorescence intensity bearing calibration and fluorescence intensity calculation element | SONY CORP | 2012-01-11 | — | — | CN | disclosed |
| US-20110177038-A1 | Inhibition of Tumor Growth via Peroxiredoxin 3 | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20100317541-A1 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy With Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101909637-A | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside | PHOENIX BIOTECHNOLOGY INC | 2010-12-08 | — | — | CN | disclosed |
| US-20100267846-A1 | MOLECULAR DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-10-21 | — | — | US | disclosed |
| EP-2231165-A1 | METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE | Phoenix Biotechnology, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2205264-A1 | MOLECULAR DELIVERY VESICLE | The University of Queensland (AU) | 2010-07-14 | — | — | EP | disclosed |
| US-20100166833-A1 | Compositions, articles and methods for preventing or reducing tobacco-associated damage | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-07-01 | — | — | US | disclosed |
| EP-2152102-A2 | COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | Technion Research & Development Foundation Ltd. (IL) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009064657-A1 | METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE | PHOENIX BIOTECHNOLOGY INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009039567-A1 | MOLECULAR DELIVERY VESICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-04-02 | — | — | WO | disclosed |
| US-7476874-B2 | Self indicating radiation alert dosimeter | JP LABORATORIES, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| WO-2008136000-A2 | COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2008-11-13 | — | — | WO | disclosed |
| US-20080249043-A1 | Methods and Compositions Involving Protein Kinase C-Delta | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| US-7227158-B1 | Stick-on self-indicating instant radiation dosimeter | JP LABS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1789576-A2 | METHOD AND COMPOSITIONS INVOLVING PROTEIN KINASE-GAMMA | University of Utah Research Foundation (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276491-A9 | Therapeutic compounds | PARKER HUGHES INSTITUTE (US) | 2006-12-07 | — | — | US | disclosed |
| US-7091351-B2 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060145091-A1 | Self indicating radiation alert dosimeter | JP LABORATORIES INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060106006-A1 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2006012518-A2 | METHOD AND COMPOSITIONS INVOLVING PROTEIN KINASE-δ | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1599744-A2 | SELF-INDICATING RADIATION ALERT DOSIMETER | JP LABORATORIES, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1105378-B1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INST (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1510212-A1 | Use of 4-substituted-quinazoline derivatives for producing therapeutic agents | Parker Hughes Institute (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040235815-A1 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE | 2004-11-25 | — | — | US | disclosed |
| US-20040192711-A1 | Therapeutic compounds | PARKER HUGHES INSTITUTE | 2004-09-30 | — | — | US | disclosed |
| WO-2004077097-A2 | SELF-INDICATING RADIATION ALERT DOSIMETER | JP LABORATORIES INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6743786-B2 | ORGANOMETALLIC COMPOUND; ANTICANCER, ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2004-06-01 | — | — | US | disclosed |
| US-6670138-B2 | Diagnosing and detecting stroke in humans; obtain tissue sample, detect expression of uncoupling proteins, evaluate for stroke | AGY THERAPEUTICS, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030228294-A1 | Controlling gene expression; supplying antibody to tumor cells; supplying enzyme inhibitor | THE JOHN HOPKINS UNIVERSITY | 2003-12-11 | — | — | US | disclosed |
| WO-2003087312-A2 | INHIBITION OF TUMOR GROWTH VIA PEROXIREDOXIN 3 | THE JOHNS HOPKINS UNIVERSITY (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030149045-A1 | Therapeutic compounds | FATIH M UCKUN | 2003-08-07 | — | — | US | disclosed |
| EP-1330548-A2 | METHODS OF DIAGNOSING, PREVENTING AND TREATING NEUROLOGICAL DISORDERS AND NEURONAL INJURIES | Agy Therapeutics, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030110840-A1 | Systems and methods for detecting a particle | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-06-19 | — | — | US | disclosed |
| US-6495556-B2 | TREATING LEUKEMIA AND LYMPHOMA, SUNBURN AND SKIN CANCER | PARKER HUGHES INSTITUTE | 2002-12-17 | — | — | US | disclosed |
| US-20020172958-A1 | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | AGY THERAPEUTICS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| US-6469013-B2 | JANUS KINASE (JAK3) INHIBITORS SUCH AS 4-(4'-HYDROXYLPHENYL)-AMINO-6,7-DIMETHOXYQUINAZOLINE; TREATING UV-B RADIATION INDUCED SKIN DAMAGE; TREATING AUTOIMMUNE DISEASES, LEUKEMIA, LYMPHOMA | PARKER HUGHES INSTITUTE | 2002-10-22 | — | — | US | disclosed |
| US-6432941-B1 | ANTICANCER, ANTITUMOR AGENT | PARKER HUGHES INSTITUTE | 2002-08-13 | — | — | US | disclosed |
| WO-2002036829-A2 | METHODS OF DIAGNOSING, PREVENTING AND TREATING NEUROLOGICAL DISORDERS AND NEURONAL INJURIES | AGY THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020042513-A1 | Therapeutic compounds | PARKER HUGHES INSTITUTE | 2002-04-11 | — | — | US | disclosed |
| US-6323039-B1 | CONTACTING SAMPLE COMPRISING ONE OR MORE MITOCHONDRIA WITH EACH OF FIRST AND SECOND ENERGY TRANSFER MOLECULE THAT IS NOT ENDOGENOUS TO THE MITOCHONDRIA; EXCITING ENERGY DONOR MOLECULE TO PRODUCE AN EXCITED ENERGY DONOR MOLECULE; DETECTING SIGNAL | MITOKOR | 2001-11-27 | — | — | US | disclosed |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | PARKER HUGHES INSTITUTE (US) | 2001-11-22 | — | — | US | disclosed |
| US-6313129-B1 | ADMINISTERING TO A MAMMAL QUINAZOLINE DERIVATIVE FOR THERAPY OF ORGAN TRANSPLANT REJECTION | HUGHES INSTITUTE | 2001-11-06 | — | — | US | disclosed |
| US-20010021526-A1 | Cellular and animal models for diseases associated with mitochondrial defects | DAVIS ROBERT E (US) | 2001-09-13 | — | — | US | disclosed |
| US-6280981-B1 | MONITORING SUBCELLULAR COMPARTMENTS SUCH AS ORGANELLES BY ENERGY TRANSFER TECHNIQUES THAT DO NOT REQUIRE SPECIFIC INTERMOLECULAR AFFINITY BINDING EVENTS BETWEEN ENERGY TRANSFER DONOR AND ENERGY TRANSFER ACCEPTOR MOLECULES | MITOKOR | 2001-08-28 | — | — | US | disclosed |
| EP-1105378-A1 | QUINAZOLINE DERIVATIVES | Parker Hughes Institute (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1104432-A1 | VANADIUM COMPOUNDS FOR TREATING CANCER | Parker Hughes Institute (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000035930-A1 | VANADIUM COMPOUNDS FOR TREATING CANCER | PARKER HUGHES INSTITUTE (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000010981-A1 | QUINAZOLINE DERIVATIVES | PARKER HUGHES INSTITUTE (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5888498-A | SCREENING DRUGS, THERAPY | MITOKOR (US) | 1999-03-30 | — | — | US | disclosed |
| US-5888498-A | SCREENING DRUGS, THERAPY | MITOKOR (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (33 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957700-B2 | Azithromycin and roxithromycin derivatives as senolytic drugs | TFEB, RHEB, RPTOR | CDC25A 305/4885CES1 2352/4885MEN1 4874/4885 |
| US-11918597-B2 | Triple combination therapies for anti-aging | TUFM, TFAM, IMMT | CDC25A 1294/4885CES1 3802/4885MEN1 4441/4885 |
| US-20210137925-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | FIS1, DNM1L, MFN2 | CDC25A 494/4885CES1 3845/4885MEN1 3161/4885 |
| US-10259775-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | CDC25A 4145/4885CES1 2161/4885MEN1 2844/4885 |
| US-20060276491-A9 | Therapeutic compounds | JAK3, JAK1, JAK2 | CDC25A 248/4885CES1 3844/4885MEN1 3689/4885 |
| US-20040235815-A1 | Vanadium compounds for treating cancer | VHL, TP53, VAV1 | CDC25A 634/4885CES1 3095/4885MEN1 819/4885 |
| US-11559527-B2 | Targeting mitochondrial fission through mDIVI-1 derivatives | FIS1, DNM1L, MFN2 | CDC25A 494/4885CES1 3845/4885MEN1 3161/4885 |
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | CYP27B1, TFAM, FIS1 | CDC25A 1571/4885CES1 1400/4885MEN1 2580/4885 |
| US-20240180944-A1 | AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGS | TFEB, RPTOR, UQCRC1 | CDC25A 234/4885CES1 2191/4885MEN1 4871/4885 |
| US-20230040965-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | ALDH2, ECHS1, ALDH5A1 | CDC25A 908/4885CES1 430/4885MEN1 4748/4885 |
| US-20010044442-A1 | Dimethoxy quinazolines for treating diabetes | JAK3, JAK1, JAK2 | CDC25A 173/4885CES1 3559/4885MEN1 2118/4885 |
| US-20220249438-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | UQCRC1, MT-CO2, UQCRC2 | CDC25A 2374/4885CES1 883/4885MEN1 2507/4885 |
| US-20220040316-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | TUFM, UQCRC1, UQCRC2 | CDC25A 2553/4885CES1 1600/4885MEN1 4770/4885 |
| US-20210275560-A1 | AZITHROMYCIN AND ROXITHROMYCIN DERIVTIVES AS SENOLYTIC DRUGS | TFEB, RPTOR, UQCRC1 | CDC25A 234/4885CES1 2191/4885MEN1 4871/4885 |
| US-20160047830-A1 | LYSOPHOSPHATIDIC ACID DETECTION | LPAR6, LPAR1, LPAR2 | CDC25A 1819/4885CES1 418/4885MEN1 3647/4885 |
| US-20100166833-A1 | Compositions, articles and methods for preventing or reducing tobacco-associated damage | SOD1, SOD3, MGMT | CDC25A 2408/4885CES1 1338/4885MEN1 2843/4885 |
| US-20220033424-A1 | FLUOROUS METAL CHELATES COMPOSITIONS | KAT6A, SLC6A12, SLC6A6 | CDC25A 4800/4885CES1 2131/4885MEN1 269/4885 |
| US-20190292135-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | CDC25A 4145/4885CES1 2161/4885MEN1 2844/4885 |
| US-20170304251-A1 | AVOCADO-DERIVED LIPIDS FOR USE IN TREATING LEUKEMIA | MCL1, ACOX1, ALOX12 | CDC25A 2404/4885CES1 370/4885MEN1 3399/4885 |
| US-20210254177-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | ALDH2, ALDH5A1, ECHS1 | CDC25A 1244/4885CES1 486/4885MEN1 4639/4885 |
| US-20220016151-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | TUFM, TFAM, IMMT | CDC25A 1294/4885CES1 3802/4885MEN1 4441/4885 |
| US-20160297748-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | CDC25A 4145/4885CES1 2161/4885MEN1 2844/4885 |
| US-20030149045-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | CDC25A 248/4885CES1 3844/4885MEN1 3689/4885 |
| US-20210275543-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL GENETIC DISEASES | HSPA9, TUFM, MT-ATP6 | CDC25A 2459/4885CES1 4288/4885MEN1 2096/4885 |
| US-20210215702-A1 | BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE | TFAM, TUFM, RARS2 | CDC25A 1274/4885CES1 1194/4885MEN1 1392/4885 |
| US-20120012123-A1 | COMPOSITIONS, ARTICLES AND METHODS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | SOD1, SOD3, MGMT | CDC25A 2408/4885CES1 1338/4885MEN1 2843/4885 |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | CYP27B1, TFAM, FIS1 | CDC25A 1571/4885CES1 1400/4885MEN1 2580/4885 |
| US-20170217907-A1 | QUINAZOLINE SCAFFOLD BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TSPO, NLN, MCU | CDC25A 4395/4885CES1 3689/4885MEN1 3856/4885 |
| US-11192849-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | CDC25A 4145/4885CES1 2161/4885MEN1 2844/4885 |
| US-20060106006-A1 | Vanadium compounds for treating cancer | VHL, TP53, VAV1 | CDC25A 634/4885CES1 3095/4885MEN1 819/4885 |
| US-20040192711-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | CDC25A 248/4885CES1 3844/4885MEN1 3689/4885 |
| US-20020042513-A1 | Therapeutic compounds | JAK3, JAK1, JAK2 | CDC25A 248/4885CES1 3844/4885MEN1 3689/4885 |
| US-10035780-B2 | Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof | TSPO, NLN, MCU | CDC25A 4395/4885CES1 3689/4885MEN1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.